{"bill": {"#text": "\n\t", "form": {"current-chamber": {"#tail": "\n\t\t", "#text": "IN THE HOUSE OF REPRESENTATIVES"}, "#text": "\n\t\t", "congress": {"#tail": "\n\t\t", "#text": "113th CONGRESS"}, "#tail": "\n\t", "legis-num": {"#tail": "\n\t\t", "#text": "H. R. 2521"}, "official-title": {"#tail": "\n\t", "#text": "To amend the Public Health Service Act to expand and\n\t\t  intensify programs of the National Institutes of Health and the Centers for\n\t\t  Disease Control and Prevention with respect to translational research and\n\t\t  related activities concerning cavernous angioma, and for other\n\t\t  purposes."}, "session": {"#tail": "\n\t\t", "#text": "1st Session"}, "distribution-code": {"#tail": "\n\t\t", "@display": "yes", "#text": "I"}, "action": {"action-date": {"#tail": "\n\t\t\t", "@date": "20130626", "#text": "June 26, 2013"}, "#tail": "\n\t\t", "action-desc": {"#tail": "\n\t\t", "#text": "\n        ", "committee-name": {"#tail": "\n      ", "@committee-id": "HIF00", "#text": "Committee on Energy and\n\t\t\t Commerce"}, "sponsor": {"#tail": " (for himself, ", "#text": "Mr. Ben Ray Luj\u00e1n of New\n\t\t\t Mexico", "@name-id": "L000570"}, "cosponsor": [{"#tail": ", and ", "#text": "Ms. Michelle Lujan\n\t\t\t Grisham of New Mexico", "@name-id": "L000580"}, {"#tail": ") introduced the following bill; which was referred to the\n\t\t\t ", "#text": "Mr.\n\t\t\t Pearce", "@name-id": "P000588"}]}, "#text": "\n\t\t\t"}, "legis-type": {"#tail": "\n\t\t", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-House", "@bill-type": "olc", "@dms-id": "H1806CD56251A4667BF862DC646C69860", "@public-private": "public", "legis-body": {"#tail": "\n", "@style": "OLC", "section": [{"@section-type": "section-one", "#tail": "\n    ", "text": {"#tail": "\n\t\t", "quote": {"short-title": {"#tail": "\n        ", "#text": "Cavernous Angioma Research Resource\n\t\t\t Act of 2013"}, "#tail": ".", "#text": "\n          "}, "#text": "This Act may be cited as the\n\t\t\t ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title"}, "#text": "\n      ", "@id": "H582597085BCE4261BBE16C8C3F64D566"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " makes the following\n\t\t\t findings:", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}, "#text": "\n        ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n      ", "#text": "Findings"}, "paragraph": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "quote": [{"#tail": " or\n\t\t\t ", "#text": "cerebral cavernous malformations"}, {"#tail": ", affects an estimated 1,500,000 people in the United\n\t\t\t States.", "#text": "CCM"}], "#text": "Cavernous angioma,\n\t\t\t also termed "}, "enum": {"#tail": "\n        ", "#text": "(1)"}, "@id": "H2EEFBC3F3BBA4F26B29F16A14647711A", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "Cavernous angioma\n\t\t\t is a devastating blood vessel disease that is characterized by the presence of\n\t\t\t vascular lesions that develop and grow within the brain and spinal cord."}, "enum": {"#tail": "\n        ", "#text": "(2)"}, "@id": "H7C1BDD531FBB4E9794772BAC242F17D0", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "Detection of\n\t\t\t cavernous angioma lesions is achieved through costly and specialized medical\n\t\t\t imaging techniques. These techniques are often not readily available where\n\t\t\t patients live, and require sedation for children and disabled adults."}, "enum": {"#tail": "\n        ", "#text": "(3)"}, "@id": "H0DFC6DE2DDEF432D97F87AB523CC14D8", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "Cavernous angioma\n\t\t\t is a common type of vascular anomaly, but individuals may not be aware that\n\t\t\t they have the disease until the onset of serious clinical symptoms. In the\n\t\t\t genetic forms, they may not be aware that it may be passed on to their\n\t\t\t children."}, "enum": {"#tail": "\n        ", "#text": "(4)"}, "@id": "H8DF7DE409076485EB7E65340B9D5818E", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "Individuals\n\t\t\t diagnosed with cavernous angioma may experience neurological deficits, seizure,\n\t\t\t stroke, or sudden death."}, "enum": {"#tail": "\n        ", "#text": "(5)"}, "@id": "H3C0FFE1A5E6C414FA90BA1E37D7B4821", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "Due to limited\n\t\t\t research with respect to cavernous angioma, there is no treatment regimen for\n\t\t\t the disease other than brain and spinal surgery."}, "enum": {"#tail": "\n        ", "#text": "(6)"}, "@id": "HB0B6E9D62EB54121B64707FF031759CE", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "Some individuals\n\t\t\t with cavernous angioma are not candidates for brain surgery. No alternative\n\t\t\t treatment option is available for such individuals."}, "enum": {"#tail": "\n        ", "#text": "(7)"}, "@id": "H14F3BD8E8CA54FC08E667A98F29777E1", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "There is a\n\t\t\t shortage of physicians who are familiar with cavernous angioma and affected\n\t\t\t individuals may find it difficult to receive timely diagnosis and appropriate\n\t\t\t care."}, "enum": {"#tail": "\n        ", "#text": "(8)"}, "@id": "H09F0E5F1C899481FB2D0C889E1FB0D50", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "quote": {"#tail": " that has passed through as many as 17 generations of\n\t\t\t Americans descended from the original Spanish settlers of the Southwest in the\n\t\t\t 1590s, New Mexico has the highest population density of cavernous angioma in\n\t\t\t the world. Cavernous angioma affects thousands of individuals in New Mexico and\n\t\t\t with ancestry in New Mexico.", "#text": "common\n\t\t\t Hispanic mutation"}, "#text": "Due to the\n\t\t\t presence of a specific disease-causing mutation, termed the "}, "enum": {"#tail": "\n        ", "#text": "(9)"}, "@id": "H30B5405287DE4A3B92871ABD1684C646", "#text": "\n        "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "#text": "Other States with\n\t\t\t high rates of cavernous angioma due to the common Hispanic Mutation include\n\t\t\t Texas, Arizona, and Colorado."}, "enum": {"#tail": "\n        ", "#text": "(10)"}, "@id": "H5CD81EF369224FCFA09AF52F0E605841", "#text": "\n        "}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "To address the\n\t\t\t public health threat posed by cavernous angioma in New Mexico and throughout\n\t\t\t the United States, there is a need to identify institutions capable of running\n\t\t\t clinical trial for this debilitating brain disorder."}, "enum": {"#tail": "\n        ", "#text": "(11)"}, "@id": "H774AF896F6A44620AD3C36B73633665F", "#text": "\n        "}], "#text": "\n      ", "@id": "H8B0F97B84D1740FF9BBF893B94343E4B"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by\n\t\t\t adding at the end the following:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Part B of\n\t\t\t title IV of the Public Health Service Act", "@value": "Public Health Service Act/t:IV/pt:B"}, "@entity-type": "law-citation", "#text": "\n          ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "42 U.S.C. 284 et seq.", "@value": "usc/42/284/etseq"}, "@parsable-cite": "usc/42/284", "#text": "\n            ", "@legal-doc": "usc"}}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "3."}, "header": {"#tail": "\n      ", "#text": "Cavernous angioma\n\t\t\t research activities"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n      ", "#text": "."}, "#tail": "\n\t\t", "section": {"#tail": "\n        ", "enum": {"#tail": "\n          ", "#text": "409K."}, "header": {"#tail": "\n\t\t\t\t\t", "#text": "Cavernous\n\t\t\t\tangioma research activities"}, "subsection": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", acting through the director of the ", "@entity-type": "federal-body", "#text": "Director of\n\t\t\t\tNIH", "@entity-id": "7529"}, {"#tail": ", shall expand and intensify programs of the ", "@entity-type": "federal-body", "#text": "National Institute of Neurological\n\t\t\t\tDisorders and Stroke", "@entity-id": "7529"}, {"#tail": " or may award grants and cooperative agreements to public\n\t\t\t\tor nonprofit private entities (including State health departments, political\n\t\t\t\tsubdivisions of States, universities, and other educational entities) for\n\t\t\t\tresearch and related activities concerning cavernous angioma.", "@entity-type": "federal-body", "#text": "National\n\t\t\t\tInstitutes of Health", "@entity-id": "7529"}], "#text": "The "}, "enum": {"#tail": "\n            ", "#text": "(a)"}, "header": {"#tail": "\n            ", "#text": "Expansion,\n\t\t\t\tIntensification, and Coordination of Activities"}, "#text": "\n            ", "@id": "H137A3F3B47354EDF9D6DDBEAAFC1492A"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", the ", "@entity-type": "act", "#text": "subsection (a)", "@value": "Public Health Service Act/s:409K/ss:a", "@proposed": "true"}, {"#tail": "\n\t\t\t\tmay carry out the following:", "@entity-type": "federal-body", "#text": "Director of NIH", "@entity-id": "7529"}], "#text": "In\n\t\t\t\texpanding and intensifying programs under "}, "enum": {"#tail": "\n            ", "#text": "(b)"}, "header": {"#tail": "\n            ", "#text": "Activities"}, "paragraph": [{"#tail": "\n            ", "@id": "HA91DBC7980974B9DA259E310BFC055EC", "enum": {"#tail": "\n              ", "#text": "(1)"}, "header": {"#tail": "\n              ", "#text": "Basic,\n\t\t\t\ttranslational, and clinical research"}, "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Conduct or financially\n\t\t\t\tsupport basic, clinical, and translational research on cavernous angioma,\n\t\t\t\tincluding research on the following:"}, "#text": "\n              ", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "quote": {"#tail": ")\n\t\t\t\tmolecules.", "#text": "CCM"}, "#text": "Proteomic,\n\t\t\t\tpharmacological, and cell biological analysis of the cerebral cavernous\n\t\t\t\tmalformations (referred to in this section as the "}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@id": "HE0BBB5364AD841189B807476D1CE4687", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Continued\n\t\t\t\tdevelopment and expansion of novel animal models for cavernous angioma\n\t\t\t\tpreclinical research."}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@id": "H44A11ADB6AE14C4EBBD66A076B77EA0B", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Early detection,\n\t\t\t\tdiagnosis, and treatment of cavernous angioma."}, "enum": {"#tail": "\n                ", "#text": "(C)"}, "@id": "HC177AF57550147EC86E33B5EC388B773", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Biological\n\t\t\t\tmechanisms for lesion genesis, development, and maturation."}, "enum": {"#tail": "\n                ", "#text": "(D)"}, "@id": "HCE9F05AF64E645CDAF2DFF7DE5FAECE0", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Biological\n\t\t\t\tmechanisms for lesion bleeding and symptomology."}, "enum": {"#tail": "\n                ", "#text": "(E)"}, "@id": "H842D77C8CE3A4FFC83003781F4B16323", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Novel biomedical\n\t\t\t\tand pharmacological interventions designed to prohibit new lesion development,\n\t\t\t\tlesion growth, and lesion bleeding."}, "enum": {"#tail": "\n                ", "#text": "(F)"}, "@id": "H532D6A3959494C8EA18E01B926C1FFAC", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Contributions of\n\t\t\t\tgenetic variation to clinical presentation as targets for therapy."}, "enum": {"#tail": "\n                ", "#text": "(G)"}, "@id": "HD56F3934B0D74829B0C1DB2A79A0767A", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Identification and\n\t\t\t\tdevelopment of biomarkers to measure phenotypic variation."}, "enum": {"#tail": "\n                ", "#text": "(H)"}, "@id": "H0FA88C192AFC410EA2FF331D1F5178D0", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Research related\n\t\t\t\tto improving the quality of life for individuals with cavernous angioma and\n\t\t\t\ttheir families."}, "enum": {"#tail": "\n                ", "#text": "(I)"}, "@id": "H9953F72845FD42FCBA3997699D610DFE", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Clinical training\n\t\t\t\tprograms aimed at increasing the number of scientists and clinicians who are\n\t\t\t\ttrained to treat patients and carry out these research directions."}, "enum": {"#tail": "\n                ", "#text": "(J)"}, "@id": "H1795C21B58EB402B87C79C06587E8F0F", "#text": "\n                "}]}, {"#tail": "\n          ", "subparagraph": [{"#tail": "\n              ", "clause": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "have an\n\t\t\t\tinstitutional infrastructure that is capable of hosting a clinical trial site\n\t\t\t\tand facilitating translational projects and collaborations for clinical\n\t\t\t\ttrials;"}, "enum": {"#tail": "\n                  ", "#text": "(i)"}, "@id": "H8FE22BF30EE8423D93B81DEE6CAB2469", "#text": "\n                  "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "have the capacity\n\t\t\t\tto maintain programs dedicated to patient education, patient outreach, and\n\t\t\t\tawareness, including\u2014"}, "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "subclause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "launching a\n\t\t\t\tnational multimedia public awareness campaign;"}, "enum": {"#tail": "\n                    ", "#text": "(I)"}, "@id": "H58BBF02153D341EBBC6DF6CFE683FA25", "#text": "\n                    "}, {"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "creating and\n\t\t\t\tdistributing patient education materials for distribution by national physician\n\t\t\t\tand surgeon offices;"}, "enum": {"#tail": "\n                    ", "#text": "(II)"}, "@id": "HC2FFBDB4F5FD46AAB11AD094E515D4F6", "#text": "\n                    "}, {"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "establishing an\n\t\t\t\teducation program for elementary and secondary school nurses to facilitate\n\t\t\t\tearly detection and diagnosis of cavernous angioma in areas of high cavernous\n\t\t\t\tangioma population density;"}, "enum": {"#tail": "\n                    ", "#text": "(III)"}, "@id": "H03EDBAD0EC6847B28ABE2D70AE000393", "#text": "\n                    "}, {"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "coordinating\n\t\t\t\tregular patient and family-oriented educational conferences; and"}, "enum": {"#tail": "\n                    ", "#text": "(IV)"}, "@id": "H567CDF50F272402ABE1C55590F9A76FD", "#text": "\n                    "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "developing\n\t\t\t\tnationally relevant electronic health teaching and communication tools and a\n\t\t\t\tnetwork of professional capacity and patient and family support;"}, "enum": {"#tail": "\n                    ", "#text": "(V)"}, "@id": "HA36B8304094740C082CE6B7B5123D7B0", "#text": "\n                    "}], "#text": "\n                  ", "@id": "H8DE23349CD734B49B6C4A418C8165EC3"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "have the\n\t\t\t\tcapacity to establish and maintain communication with other major cavernous\n\t\t\t\tangioma research and care institutions internationally for information sharing\n\t\t\t\tand coordination of research activities;"}, "enum": {"#tail": "\n                  ", "#text": "(iii)"}, "@id": "H578B7CDE8CB64B7AA7BCEB57BF6EAD47", "#text": "\n                  "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "have demonstrated\n\t\t\t\tclinical expertise in cavernous angioma management;"}, "enum": {"#tail": "\n                  ", "#text": "(iv)"}, "@id": "HCBE165BB037D467E8194E550303BB542", "#text": "\n                  "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "have a sufficient\n\t\t\t\tnumber of eligible patients for participation with particular focus on unique\n\t\t\t\tsubpopulations including Common Hispanic Mutation and CCM3 gene mutation\n\t\t\t\tcarriers; and"}, "enum": {"#tail": "\n                  ", "#text": "(v)"}, "@id": "HA90E369879014BD1B2F8BDAB76D00125", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "have a telehealth\n\t\t\t\tinfrastructure to support and to provide clinical consultation for remote and\n\t\t\t\tunderserved communities."}, "enum": {"#tail": "\n                  ", "#text": "(vi)"}, "@id": "H13A895FA7E554B4789E32B2BF2CB307F", "#text": "\n                  "}], "enum": {"#tail": "\n                ", "#text": "(A)"}, "header": {"#tail": "\n                ", "#text": "Coordination"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Identify\n\t\t\t\tand support the development of a clinical and research coordinating center with\n\t\t\t\tthe potential of coordinating a multi-site clinical drug trial for cavernous\n\t\t\t\tangioma. Such coordinating center shall provide a model for additional trial\n\t\t\t\tsites, facilitate medical research to develop a cure for cavernous angioma, and\n\t\t\t\tenhance the medical care of individuals with cavernous angioma nationwide. Such\n\t\t\t\tcoordinating center shall\u2014"}, "#text": "\n                ", "@id": "HEFE6AE9799B64B43ADF7234E57E10A4B"}, {"#tail": "\n            ", "clause": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "have an\n\t\t\t\tinstitutional infrastructure capable of hosting a clinical trial site and\n\t\t\t\tfacilitating translational projects and collaborations for clinical\n\t\t\t\ttrials;"}, "enum": {"#tail": "\n                  ", "#text": "(i)"}, "@id": "H54AE228D1B05494194710BFAF918F99A", "#text": "\n                  "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "have the capacity\n\t\t\t\tto maintain communication with other major cavernous angioma research and care\n\t\t\t\tinstitutions internationally for information sharing and coordination of\n\t\t\t\tresearch activities;"}, "enum": {"#tail": "\n                  ", "#text": "(ii)"}, "@id": "HF5E4FF48C168486482EC2194AE81975E", "#text": "\n                  "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "have\n\t\t\t\tdemonstrated clinical expertise in cavernous angioma management; and"}, "enum": {"#tail": "\n                  ", "#text": "(iii)"}, "@id": "H47739A30D4754A0986CDD41B6571FBEA", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "have a sufficient\n\t\t\t\tnumbers of eligible patients for participation with particular focus on unique\n\t\t\t\tsubpopulations including Common Hispanic Mutation and CCM3 gene mutation\n\t\t\t\tcarriers as these unique populations may provide insight to other genetic and\n\t\t\t\tnon-genetic forms of the illness."}, "enum": {"#tail": "\n                  ", "#text": "(iv)"}, "@id": "HDED73DCB1F094035885435329D4DEFE4", "#text": "\n                  "}], "enum": {"#tail": "\n                ", "#text": "(B)"}, "header": {"#tail": "\n                ", "#text": "Participation"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " and other national and international centers. Such\n\t\t\t\tparticipation centers shall\u2014", "@entity-type": "act", "#text": "subparagraph (A)", "@value": "Public Health Service Act/s:409K/ss:b/p:2/sp:A", "@proposed": "true"}, "#text": "Identify\n\t\t\t\tand support the development of clinical and research participation centers with\n\t\t\t\tthe potential to participate in a multi-site clinical drug trial for cavernous\n\t\t\t\tangioma. Such participation centers may facilitate medical research to develop\n\t\t\t\ta cure for cavernous angioma and enhance the medical care of individuals with\n\t\t\t\tcavernous angioma in partnership with the coordinating center under\n\t\t\t\t"}, "#text": "\n                ", "@id": "H024A5133B74944C083F7BEFBC6EC272B"}], "enum": {"#tail": "\n              ", "#text": "(2)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Facilitation of\n\t\t\t\tresearch resources; clinical trial preparedness"}, "#text": "\n              ", "@id": "HB3BD96FE233F469EBC2DEE7996A0AEA2"}], "#text": "\n            ", "@id": "H3DA628EEA0744E5A84AA3402177B349B"}, {"#tail": "\n        ", "enum": {"#tail": "\n            ", "#text": "(c)"}, "header": {"#tail": "\n\t\t\t\t\t\t", "#text": "Training program\n\t\t\t\tfor clinicians and scientists"}, "paragraph": [{"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "#text": "Eligible coordinating and participation centers under\n\t\t\t\tthis section shall establish or expand training programs for medical and allied\n\t\t\t\thealth clinicians and scientists in clinical practice and research relevant to\n\t\t\t\tcavernous angioma."}, "enum": {"#tail": "\n              ", "#text": "(1)"}, "header": {"#tail": "\n              ", "#text": "In\n\t\t\t\tgeneral"}, "#text": "\n              ", "@id": "HC03CCF513F154B68903B1D5687303A07"}, {"#tail": "\n            ", "@id": "H1DD713FD71EC451F8211B8D9A7CD2464", "enum": {"#tail": "\n              ", "#text": "(2)"}, "header": {"#tail": "\n              ", "#text": "Research\n\t\t\t\tresources"}, "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n\t\t\t\tmay\u2014", "@entity-type": "federal-body", "#text": "Director of NIH", "@entity-id": "7529"}, "#text": "In carrying out this subsection, the "}, "#text": "\n              ", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " pursuant to other provisions of\n\t\t\t\tlaw or prior to the date of the enactment of this section;", "@entity-type": "federal-body", "#text": "National Institutes of Health", "@entity-id": "7529"}, "#text": "use information\n\t\t\t\tcollected by the "}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@id": "HEA13181301F3467E957AF50391999F43", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "take into\n\t\t\t\tconsideration the availability of other research resources;"}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@id": "H37EDBE121F8449C2AA2E644A6FE5A139", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "encourage the use\n\t\t\t\tof research resources for research on, and development of, therapies and\n\t\t\t\ttreatments for individuals with cavernous angioma; and"}, "enum": {"#tail": "\n                ", "#text": "(C)"}, "@id": "H25F3F3E803C34377973A45DF6656222A", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "federal-body", "#text": "National Institutes of Health", "@entity-id": "7529"}, "#text": "encourage the\n\t\t\t\tinclusion of individuals with cavernous angioma in clinical trials conducted or\n\t\t\t\tsupported by the "}, "enum": {"#tail": "\n                ", "#text": "(D)"}, "@id": "H9A8B6B42AB674E0BA64ACF597E0FCD21", "#text": "\n                "}]}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " may provide for the\n\t\t\t\tparticipation of agencies of the ", "@entity-type": "federal-body", "#text": "Director of NIH", "@entity-id": "7529"}, {"#tail": " in a consortium\n\t\t\t\tto facilitate the exchange of information and to make the research effort on\n\t\t\t\tcavernous angioma more efficient and effective by ensuring consistent\n\t\t\t\tcommunication, minimizing duplication of effort, and integrating the varied\n\t\t\t\tperspectives of partner agencies, organizations, and individuals. Such\n\t\t\t\tconsortium shall include at least one national cavernous angioma patient\n\t\t\t\tadvocacy organization and may be the same consortium receiving a grant or\n\t\t\t\tcontract under ", "@entity-type": "federal-body", "#text": "National Institutes of Health", "@entity-id": "7529"}, {"#tail": ".", "@entity-type": "act", "#text": "subsection\n\t\t\t\t(b)(2)(A)", "@value": "Public Health Service Act/s:409K/ss:b/p:2/sp:A", "@proposed": "true"}], "#text": "The "}, "enum": {"#tail": "\n              ", "#text": "(3)"}, "header": {"#tail": "\n              ", "#text": "Cavernous\n\t\t\t\tangioma consortium"}, "#text": "\n              ", "@id": "HB3F9425D604B4D51B197EA2E8C368D2D"}], "#text": "\n            ", "@id": "H43AB114238A748E1A93B706C2ED91EF9"}], "#text": "\n          ", "@id": "HDCA3F65EF0DD48CF8CA4797E24059B17"}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t", "@id": "H1292A22841904A29B5D29E887926D0E3"}, "#text": "\n      ", "@id": "H336827D2930943819F4F1D4AD1741549"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " the following:", "@entity-type": "act", "#text": "section 317T", "@value": "Public Health Service Act/s:317T"}, "#text": "\n        ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by\n\t\t\t inserting after ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Part B of title III\n\t\t\t of the Public Health Service Act", "@value": "Public Health Service Act/t:III/pt:B"}, "@entity-type": "law-citation", "#text": "\n          ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n          ", "@entity-type": "uscode", "#text": "42 U.S.C. 243 et seq.", "@value": "usc/42/243/etseq"}, "@parsable-cite": "usc/42/243", "#text": "\n            ", "@legal-doc": "usc"}}, "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "4."}, "header": {"#tail": "\n      ", "#text": "Centers for\n\t\t\t Disease Control and Prevention cavernous angioma surveillance and research\n\t\t\t programs"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n      ", "#text": "."}, "#tail": "\n\t\t", "section": {"#tail": "\n        ", "enum": {"#tail": "\n          ", "#text": "317U."}, "header": {"#tail": "\n\t\t\t\t\t", "#text": "Cavernous\n\t\t\t\tangioma surveillance and research programs"}, "subsection": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", acting through the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", may award grants and cooperative agreements\n\t\t\t\tto public or nonprofit private entities (including State health departments,\n\t\t\t\tpolitical subdivisions of States, universities, and other educational entities)\n\t\t\t\tfor the collection, analysis, and reporting of data on cavernous angioma. In\n\t\t\t\tmaking such awards, the ", "@entity-type": "federal-body", "#text": "Director of the Centers\n\t\t\t\tfor Disease Control and Prevention", "@entity-id": "7523"}, {"#tail": " may provide direct technical assistance,\n\t\t\t\tincluding personnel support, in lieu of cash.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "The "}, "enum": {"#tail": "\n            ", "#text": "(a)"}, "header": {"#tail": "\n            ", "#text": "In\n\t\t\t\tgeneral"}, "#text": "\n            ", "@id": "HD1541BB096FB44B1BDFD24A481D8811B"}, {"#tail": "\n        ", "enum": {"#tail": "\n            ", "#text": "(b)"}, "header": {"#tail": "\n\t\t\t\t\t\t", "#text": "National\n\t\t\t\tCavernous Angioma Epidemiology Program"}, "paragraph": [{"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", acting through the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", may award grants to public or nonprofit private entities (including\n\t\t\t\tState health departments, political subdivisions of States, universities, and\n\t\t\t\tother educational entities) for the purpose of carrying out epidemiological\n\t\t\t\tactivities regarding cavernous angioma, including collecting and analyzing\n\t\t\t\tinformation on the number, incidence, correlates, and symptoms of cases and the\n\t\t\t\tclinical utility (including costs and benefits) of specific practice patterns.\n\t\t\t\tIn making such awards, the ", "@entity-type": "federal-body", "#text": "Director of the Centers for Disease Control and\n\t\t\t\tPrevention", "@entity-id": "7523"}, {"#tail": " may provide direct technical assistance,\n\t\t\t\tincluding personnel support, in lieu of cash.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "The\n\t\t\t\t"}, "enum": {"#tail": "\n              ", "#text": "(1)"}, "header": {"#tail": "\n              ", "#text": "Grants"}, "#text": "\n              ", "@id": "H632B8EF456434B9B869CEA5DC42CE496"}, {"#tail": "\n          ", "@id": "HD7B388CB4C1D4227B1D68789A56950DF", "enum": {"#tail": "\n              ", "#text": "(2)"}, "header": {"#tail": "\n              ", "#text": "National\n\t\t\t\tsurveillance program"}, "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", the\n\t\t\t\t", "@entity-type": "act", "#text": "subsection (a)", "@value": "Public Health Service Act/s:317U/ss:a", "@proposed": "true"}, {"#tail": " shall\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "In carrying out "}, "#text": "\n              ", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "provide for a\n\t\t\t\tnational surveillance program; and"}, "enum": {"#tail": "\n                ", "#text": "(A)"}, "@id": "H8DE9B3CBB8B64A1FBBBF6178EED5F8F8", "#text": "\n                "}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " under ", "@entity-type": "federal-body", "#text": "National Institutes of Health", "@entity-id": "7529"}, {"#tail": ".", "@entity-type": "act", "#text": "section\n\t\t\t\t409K", "@value": "Public Health Service Act/s:409K", "@proposed": "true"}], "#text": "where possible,\n\t\t\t\tensure that the surveillance program is coordinated with the data and sample\n\t\t\t\tcollection activities of the "}, "enum": {"#tail": "\n                ", "#text": "(B)"}, "@id": "HE06288EBB41B4C3997379B00014E2BFC", "#text": "\n                "}]}], "#text": "\n            ", "@id": "H274B4D14F449496FB171E6C60927EA0F"}], "#text": "\n          ", "@id": "H9003A56A93884778A5DA15A4238E4431"}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t", "@id": "H373778A4658B4EC3A61312FDB60056F3"}, "#text": "\n      ", "@id": "H79F58698B6D840719B9728DB72FD8118"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "5."}, "header": {"#tail": "\n\t\t\t", "#text": "Food and Drug\n\t\t\t Administration cavernous angioma clinical trial preparedness and support\n\t\t\t program"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall\n\t\t\t work with clinical centers, investigators, and advocates to support appropriate\n\t\t\t investigational new drug application under ", "@entity-type": "federal-body", "#text": "Commissioner of Food and Drugs", "@entity-id": "7524"}, {"#tail": " in an effort to hasten the pace of clinical trials for\n\t\t\t cavernous angioma.", "@entity-type": "act", "#text": "section 505(i) of the Federal Food,\n\t\t\t Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:505/ss:i"}], "#text": "The "}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Investigational\n\t\t\t new drug application"}, "#text": "\n        ", "@id": "HFF5BF03ADAB248B18944F5B1F73A2370"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall support appropriate requests for designations of drugs as orphan\n\t\t\t drugs under ", "@entity-type": "federal-body", "#text": "Commissioner of Food and\n\t\t\t Drugs", "@entity-id": "7524"}, {"#tail": ".", "@entity-type": "act", "#text": "section 526 of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:526"}], "#text": "Where applicable in rare subpopulations of cavernous\n\t\t\t angioma requiring unique pharmacological intervention, including those with the\n\t\t\t Common Hispanic Mutation or CCM3 gene mutations, the "}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Orphan product\n\t\t\t development"}, "#text": "\n        ", "@id": "H78A4E711AF4B4693ACD72774F5BD2775"}], "#text": "\n      ", "@id": "H64F00BC8BE884A9584B816598F198DE0"}, {"#tail": "\n  ", "text": {"#tail": "\n\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall prepare and submit to the appropriate committees of the\n\t\t\t Congress a report concerning the implementation of this Act and the amendments\n\t\t\t made by this Act.", "@entity-type": "federal-body", "#text": "Secretary of Health and\n\t\t\t Human Services", "@entity-id": "7500"}, "#text": "Not later than\n\t\t\t January 1, 2015, and each January 1 thereafter, the ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "6."}, "header": {"#tail": "\n      ", "#text": "Report to\n\t\t\t congress"}, "#text": "\n      ", "@id": "H5711195351984923B39337DE15244450"}], "#text": "\n\t\t", "@id": "H676CBEC77F7E48DE91954C64B0BBC0C2"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2013-06-26"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 HR 2521 IH: Cavernous Angioma Research Resource Act of 2013"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. House of Representatives"}, "#text": "\n"}, "#text": "\n"}}}